Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies
Cells · 18.09.2025 · 14 (18) · 1458
DOI: 10.3390/cells14181458 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 18.09.2025. Verfasst von Jianan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Glioblastoma, Tumor-Associated Macrophages, Brain Neoplasms. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Strokes.
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive brain tumor with a highly immunosuppressive microenvironment that promotes tumor progression and therapy resistance. Tumor-associated macrophages (TAMs), comprising up to 50% of the tumor mass, are recruited via chemokine axes such as CCL2/CCR2, CX3CL1/CX3CR1, and CXCL12/CXCR4 and adopt an M2-like immunosuppressive phenotype, facilitating immune escape and angiogenesis. Key signaling pathways, including CSF1R, STAT3, NF-κB, PI3K/Akt, and HIF-1α, regulate TAM function, making them promising therapeutic targets. Strategies such as TAM depletion, reprogramming, and immune checkpoint blockade (PD-1/PD-L1, and CD47-SIRPα) have shown potential in preclinical models. Emerging approaches, including CAR-macrophage (CAR-M) therapy, nanotechnology-based drug delivery, and exosome-mediated modulation, offer new avenues for intervention. However, clinical translation remains challenging due to GBM’s heterogeneity and adaptive resistance mechanisms. Future research should integrate multi-omics profiling and AI-driven drug discovery to refine TAM-targeted therapies and improve patient outcomes. This review provides a comprehensive analysis of TAM-mediated immune regulation in GBM and explores evolving therapeutic strategies aimed at overcoming its treatment barriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
- Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, USA.
- Departments of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
ORCID-Profile: Jianan Chen, Qiong Wu, Robert J Macaulay, James J Mulé, Arnold B Etame
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Strokes
Zitieren
APA
Chen, J., Wu, Q., Berglund, A. E., Macaulay, R. J., Mulé, J. J., & Etame, A. B. (2025). Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies. Cells, 14(18), 1458. https://doi.org/10.3390/cells14181458
Vancouver
Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies. Cells. 2025;14(18):1458. doi:10.3390/cells14181458
BibTeX
@article{Chen2025,
author = {Chen, Jianan and Wu, Qiong and Berglund, Anders E and Macaulay, Robert J and Mulé, James J and Etame, Arnold B},
title = {Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies},
journal = {Cells},
year = {2025},
volume = {14},
number = {18},
pages = {1458},
doi = {10.3390/cells14181458}
}
EUVIMED